Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer

Journal of Personalized Medicine

卷:11

Carlo Buonerba¹  Felice Crocetto²  Daniela Terracciano³  Antonietta Liotti³  Michele Cennamo³  Evelina La Civita³  GianMaria Busetto⁴  Matteo Ferro⁵  Ottavio de Cobelli⁵  Giuseppe Carrieri⁶  Francesco Del Giudice⁶  Angelo Porreca⁷  Amelia Cimmino⁸  Fabiana Tortora⁹  Giuseppe Lucarelli¹⁰ 

[1] CRTR Rare Tumors Reference Center, AOU Federico II, 80131 Naples, Italy;

[2] Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy;

[3] Department of Translational Medical Sciences, University of Naples “Federico II”, 80131 Naples, Italy;

[4] Department of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy;

[5] Department of Urology of European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy;

[6] Department of Urology, Sapienza University of Rome, 00185 Rome, Italy;

[7] Department of Urology, Veneto Institute of Oncology, 31033 Padua, Italy;

[8] Institute of Genetics and Biophysics, National Research Council, 80131 Naples, Italy;

[9] Institute of Protein Biochemistry, National Research Council, 80131 Naples, Italy;

[10] Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, 70124 Bari, Italy;

关键词: bladder cancer;    liquid biopsy;    free nucleic acids;    urinary biomarkers;   

DOI  :  10.3390/jpm11030237

来源: DOAJ

【 摘 要 】

Bladder cancer (BC) is characterized by high incidence and recurrence rates together with genomic instability and elevated mutation degree. Currently, cystoscopy combined with cytology is routinely used for diagnosis, prognosis and disease surveillance. Such an approach is often associated with several side effects, discomfort for the patient and high economic burden. Thus, there is an essential demand of non-invasive, sensitive, fast and inexpensive biomarkers for clinical management of BC patients. In this context, liquid biopsy represents a very promising tool that has been widely investigated over the last decade. Liquid biopsy will likely be at the basis of patient selection for precision medicine, both in terms of treatment choice and real-time monitoring of therapeutic effects. Several different urinary biomarkers have been proposed for liquid biopsy in BC, including DNA methylation and mutations, protein-based assays, non-coding RNAs and mRNA signatures. In this review, we summarized the state of the art on different available tests concerning their potential clinical applications for BC detection, prognosis, surveillance and response to therapy.

【 授权许可】

Unknown